FDA Grants AP Status for Risperidone ANDA077494 Submission
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Risperidone under application number ANDA077494.
Asset
Risperidone
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's grant of Abbreviated New Drug Application (ANDA) approval status for Risperidone indicates a significant shift in the competitive landscape. This could lead to increased market competition and pressure on pricing strategies for current branded products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for final approval and market entry of the generic Risperidone by PH HEALTH.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.